Jazz Pharmaceuticals Files 8-K Report
Ticker: JAZZ · Form: 8-K · Filed: Oct 22, 2025 · CIK: 1232524
| Field | Detail |
|---|---|
| Company | Jazz Pharmaceuticals PLC (JAZZ) |
| Form Type | 8-K |
| Filed Date | Oct 22, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $90 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, 8-K
TL;DR
Jazz Pharma filed an 8-K on 10/21/25, confirming their Dublin HQ and contact info.
AI Summary
On October 21, 2025, Jazz Pharmaceuticals plc filed an 8-K report. The filing indicates that the company is located at Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland, with a business phone number of 011-353-1-634-7800. This report is a current report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Why It Matters
This 8-K filing serves as a public notification of Jazz Pharmaceuticals plc's current reporting status and provides key corporate information, including its address and contact details.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not contain information that suggests a significant change in the company's risk profile.
Key Players & Entities
- Jazz Pharmaceuticals plc (company) — Registrant
- October 21, 2025 (date) — Date of earliest event reported
- Dublin 4, Ireland (location) — Address of principal executive offices
- 011-353-1-634-7800 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to serve as a current report filed by Jazz Pharmaceuticals plc pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting on other events.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on October 21, 2025.
Where are Jazz Pharmaceuticals plc's principal executive offices located?
Jazz Pharmaceuticals plc's principal executive offices are located at Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland.
What is the registrant's telephone number?
The registrant's telephone number is 011-353-1-634-7800.
What is the SIC code for Jazz Pharmaceuticals plc?
The Standard Industrial Classification (SIC) code for Jazz Pharmaceuticals plc is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,259 words · 5 min read · ~4 pages · Grade level 16.6 · Accepted 2025-10-22 09:01:49
Key Financial Figures
- $0.0001 — istered Ordinary shares, nominal value $0.0001 per share JAZZ The Nasdaq Stock Mar
- $90 million — ompany has agreed to (a) pay a total of $90 million in a lump sum in settlement of Avadel's
Filing Documents
- d65147d8k.htm (8-K) — 27KB
- 0001193125-25-245815.txt ( ) — 143KB
- jazz-20251021.xsd (EX-101.SCH) — 3KB
- jazz-20251021_lab.xml (EX-101.LAB) — 18KB
- jazz-20251021_pre.xml (EX-101.PRE) — 11KB
- d65147d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements, including, but not limited to, all statements related to the Settlement Agreement, including the rights and obligations thereunder, as well as the expected amount, timing and source of funding of the pre-tax charge in connection therewith. These forward-looking statements are based on the Company's current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Do not place undue reliance on these forward-looking statements, which speak only as of the date hereof. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risk that the Settlement Agreement may not have the expected impact or may require more activity or expense than expected, the risk that the Company may incur other charges or cash expenditures not currently contemplated due to unanticipated events that may occur, including in connection with the implementation of the Settlement Agreement, and other risks. These and other risks and uncertainties relating to the Company and its business can be found under the caption "Risk Factors" and elsewhere in the Company's Securities and Exchange Commission filings and reports, including the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and Current Report on Form 10-Q for the quarterly period ended June 30, 2025, as well as future filings and reports by the Company. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this Current Report on Form 8-K as a result of new information, future events or changes in its expectations.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY By: /s/ Neena Patil Name: Neena Patil Title: Executive Vice President and Chief Legal Officer Date: October 22, 2025